Outcomes of expanded use of PCA3 testing in a Spanish population with clinical suspicion of prostate cancer
暂无分享,去创建一个
J. López-Guerrero | E. Solsona | J. Casanova | B. Ortiz | I. Iborra | J. Ricós | J. Monrós | J. Rubio-Briones | R. Dumont | A. Fernández-Serra | A. Collado | Á. Gómez-Ferrer | M. Ramírez | L. Rubio | Z. Garcia-Casado | Á. Gómez‐Ferrer | Z. García-Casado | M. Ramirez
[1] F. Schröder,et al. Screening for prostate cancer. , 2011, European journal of cancer.
[2] M. Colombel,et al. Urinary PCA3 score predicts prostate cancer multifocality. , 2011, The Journal of urology.
[3] L. Salomon,et al. Prostate cancer antigen 3 score accurately predicts tumour volume and might help in selecting prostate cancer patients for active surveillance. , 2011, European urology.
[4] E. Colás,et al. PSGR and PCA3 as biomarkers for the detection of prostate cancer in urine , 2010, The Prostate.
[5] A. Bjartell,et al. PCA3 as a diagnostic marker for prostate cancer: A validation study on a Swedish patient population , 2010, Scandinavian journal of urology and nephrology.
[6] G. Andriole,et al. PCA3 molecular urine test for predicting repeat prostate biopsy outcome in populations at risk: validation in the placebo arm of the dutasteride REDUCE trial. , 2010, The Journal of urology.
[7] A. Haese*,et al. The prostate cancer gene 3 (PCA3) urine test in men with previous negative biopsies: does free‐to‐total prostate‐specific antigen ratio influence the performance of the PCA3 score in predicting positive biopsies? , 2010, BJU international.
[8] R. V. D. van den Bergh,et al. Performance of the prostate cancer antigen 3 (PCA3) gene and prostate-specific antigen in prescreened men: exploring the value of PCA3 for a first-line diagnostic test. , 2010, European urology.
[9] Erik Holmberg,et al. Mortality results from the Göteborg randomised population-based prostate-cancer screening trial. , 2010, The Lancet. Oncology.
[10] J. López-Guerrero,et al. Clinical implications of TMPRSS2-ERG gene fusion expression in patients with prostate cancer treated with radical prostatectomy. , 2010, The Journal of urology.
[11] A. Stenzl,et al. Interpretation of the Prostate Cancer Gene 3 in Reference to the Individual Clinical Background: Implications for Daily Practice , 2010, Urologia Internationalis.
[12] J. Ruiz-Aragón,et al. Evaluación del test PCA3 para el diagnóstico de cáncer de próstata: revisión sistemática y metanálisis , 2010 .
[13] B. G. Blijenberg,et al. Screening and prostate-cancer mortality in a randomized European study. , 2009, The New England journal of medicine.
[14] David Chia,et al. Mortality results from a randomized prostate-cancer screening trial. , 2009, The New England journal of medicine.
[15] W. Ellis,et al. Prostate cancer gene 3 (PCA3): development and internal validation of a novel biopsy nomogram. , 2009, European urology.
[16] John T. Wei,et al. Rational approach to implementation of prostate cancer antigen 3 into clinical care , 2009, Cancer.
[17] J. Oppenheimer,et al. PCA3 urine mRNA testing for prostate carcinoma: patterns of use by community urologists and assay performance in reference laboratory setting. , 2009, Urology.
[18] Mesut Remzi,et al. Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy. , 2008, European urology.
[19] P. Troncoso,et al. PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance. , 2008, The Journal of urology.
[20] Seongjoon Koo,et al. PCA3: a molecular urine assay for predicting prostate biopsy outcome. , 2008, The Journal of urology.
[21] W. Ellis,et al. A multicenter evaluation of the PCA3 molecular urine test: pre-analytical effects, analytical performance, and diagnostic accuracy. , 2008, Clinica chimica acta; international journal of clinical chemistry.
[22] Jianjun Yu,et al. A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer. , 2008, Cancer research.
[23] J. Witjes,et al. Detection of TMPRSS2-ERG Fusion Transcripts and Prostate Cancer Antigen 3 in Urinary Sediments May Improve Diagnosis of Prostate Cancer , 2007, Clinical Cancer Research.
[24] Amy Blase,et al. PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy. , 2007, Urology.
[25] J. Crowley,et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. , 2004, The New England journal of medicine.
[26] Harry J de Koning,et al. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. , 2003, Journal of the National Cancer Institute.
[27] W. Isaacs,et al. DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. , 1999, Cancer research.
[28] R. Autorino,et al. Prostate cancer detection in the "grey area" of prostate-specific antigen below 10 ng/ml: head-to-head comparison of the updated PCPT calculator and Chun's nomogram, two risk estimators incorporating prostate cancer antigen 3. , 2011, European urology.
[29] A. Haese*,et al. Critical assessment of preoperative urinary prostate cancer antigen 3 on the accuracy of prostate cancer staging. , 2011, European urology.
[30] S. Márquez-Peláez,et al. [Assessment of the PCA3 test for prostate cancer diagnosis: a systematic review and meta-analysis]. , 2010, Actas urologicas espanolas.
[31] W. Ellis,et al. Reply to Juan Morote’s Letter to the Editor re: Felix K. Chun, Alexandre de la Taille, Hendrik van Poppel, et al. Prostate Cancer Gene 3 (PCA3): Development and Internal Validation of a Novel Biopsy Nomogram. Eur Urol 2009;56:659–68 , 2010 .
[32] J. Witjes,et al. Predictive value of PCA3 in urinary sediments in determining clinico‐pathological characteristics of prostate cancer , 2010, The Prostate.